CN112724241B - Purification method of abamectin - Google Patents
Purification method of abamectin Download PDFInfo
- Publication number
- CN112724241B CN112724241B CN202011638764.5A CN202011638764A CN112724241B CN 112724241 B CN112724241 B CN 112724241B CN 202011638764 A CN202011638764 A CN 202011638764A CN 112724241 B CN112724241 B CN 112724241B
- Authority
- CN
- China
- Prior art keywords
- solution
- mobile phase
- acetonitrile
- crude peptide
- taking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
Abstract
The invention discloses a purification method of abamectin, belonging to the technical field of polypeptide drug purification. The method comprises the steps of taking the abapatatin crude peptide for pretreatment, dissolving the abapatatin crude peptide into acetonitrile water solution, and obtaining crude peptide solution. Then taking the crude peptide solution, carrying out isocratic and gradient elution on a mixed solution of the A1 solution, the A2 solution and the B solution, and collecting eluted components to obtain a first purified substance; taking the first purified product, carrying out salt conversion isocratic elution on the mixed solution of the A3 solution and the B solution, and collecting the eluted components to obtain the final purified product; finally, the final purified product is subjected to reduced pressure rotary steaming concentration and freeze drying to obtain an abapatulin finished product; the preparation method of the abapatatin prepared by the purification method has the advantages of simple steps, low raw material consumption, high product yield and high purity, and is suitable for large-scale industrial production.
Description
Technical Field
The invention relates to the technical field of polypeptide drug purification, and particularly relates to a purification method of abamectin.
Background
Abappicin, english name Abaloparatide.
The abapatulin is a polypeptide consisting of 34 amino acid residues, has a molecular formula of C174H300N56O49, a molecular weight of 3960.64g/mol, a CAS number of 247062-33-5, and a structure as follows:
Ala1-Val2-Ser3-Glu4-His5-Gln6-Leu7-Leu8-His9-Asp10-Lys11-Gly12-Lys13Ser14-Ile15-Gln16-Asp17-Leu18-Arg19-Arg20-Arg21-Glu22-Leu23-Leu24-Glu25Lys26-Leu27-Leu28-Aib29-Lys30-Leu31-His32-Thr33-Ala34-NH2。
parathyroid hormone (PTH) is a polypeptide hormone secreted from the parathyroid chief cell and regulating calcium and phosphorus metabolism in vivo, and has a C-terminal peptide chain which binds to PTH-II receptor to promote bone apoptosis and an N-terminal peptide chain which binds to PTH-I receptor to promote bone remodeling.
Abapatide (Abalopratide), a novel parathyroid hormone-related peptide (PTHrP) developed by Radius Health, is a potent selective activator of PTH-I receptor, increases bone mineral content, bone density and bone strength, promotes bone formation, has been approved by the FDA on 28/4.2017 and is marketed under the name Tymlos.
Abapatide is injected subcutaneously to treat osteoporosis in postmenopausal women at risk of fracture or ineffective to other therapeutic agents, and is effective in reducing fracture rate of new vertebral body and non-vertebral body.
The solid-phase synthesis of the abapatulin generates a large amount of impurities, and the existing purification method has low yield and is complex and difficult to operate.
Disclosure of Invention
The invention aims to solve the defects of the prior art and provides a novel method for purifying the abapa peptide, which can effectively remove various impurities generated by synthesis to obtain the high-purity abapa peptide.
The object of the present invention is achieved by the following means. The invention relates to a purification method of abamectin, which comprises the following specific technical scheme:
the method comprises the following steps: the abapatatin crude peptide is taken to be pretreated and dissolved in acetonitrile water solution to obtain crude peptide solution.
Step two: taking the crude peptide solution, carrying out isocratic and gradient elution on a mixed solution of the A1 solution, the A2 solution and the B solution, and collecting eluted components to obtain a first purified substance;
step three: taking the first purified product, carrying out desalination isocratic elution on a mixed solution of the A3 solution and the B solution, and collecting eluted components to obtain a final purified product;
step four: carrying out reduced pressure rotary steaming concentration and freeze drying on the final purified product to obtain an abapatulin finished product;
the solution A1 is a 10% acetic acid aqueous solution;
the A2 solution is 0.1% aqueous TFA;
the A3 solution is pure water;
the solution B is 100% acetonitrile.
Preferably, the method for purifying abamectin comprises the step of pretreating abamectin, which comprises:
dissolving the abamectin in acetonitrile water solution to obtain a crude abamectin peptide water solution;
insoluble particles in the crude abapatulin peptide water solution are removed by a filter membrane, and the filtrate is collected.
Preferably, the purification method of the abapatatin comprises the following specific steps:
taking an octaalkylsilane bonded silica chromatographic column as a stationary phase, 10% acetic acid as a mobile phase A1 and acetonitrile as a mobile phase B, carrying out isocratic elution at a detection wavelength of 260nm, then taking a 0.1% TFA aqueous solution as a mobile phase A2 and acetonitrile as a mobile phase B, carrying out gradient elution at a detection wavelength of 225nm, and collecting fractions containing the abamectin.
The preferable purification method of the abapatulin comprises the following three specific steps:
performing isocratic elution by using a tetraalkylsilane bonded silica gel chromatographic column as a stationary phase, pure water as a mobile phase A3 and acetonitrile as a mobile phase B, wherein the detection wavelength is 225nm, the volume fraction ratio of the pure water to the acetonitrile solution is 40% to 60%, and the isocratic elution time is 30-40 min;
preferably, the method for purifying abapatulin comprises the following specific steps:
the water bath temperature of the rotary evaporator is 30 ℃, the vacuum degree is-0.008 MP, and the freeze drying is finished in a vacuum freeze dryer after removing acetonitrile.
Compared with the prior art, the invention has the following beneficial effects:
the invention provides a method for purifying abamectin, which comprises the steps of dissolving crude abamectin in acetonitrile water, filtering to obtain a crude peptide solution, and carrying out one-step purification and one-step desalination to obtain the abamectin. The yield is about 70 percent, the purity is more than 99.0 percent, and the single impurity content is less than 0.15 percent. The invention can effectively solve the problems of low purity and low yield of the abapa peptide finished product.
Detailed Description
The invention discloses a purification method of abamectin. The method may be carried out by those skilled in the art with reference to the disclosure herein, and it is specifically intended that all such alterations and modifications as are obvious to those skilled in the art are deemed to be included in the invention. While the purification methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications of the methods and applications described herein, as well as appropriate variations and combinations thereof, may be made to implement and use the techniques of the present invention without departing from the spirit and scope of the invention.
Embodiment 1, a purification method of abapa peptide, the specific technical scheme includes:
the method comprises the following steps: taking the abapa peptide crude peptide for pretreatment, and dissolving the abapa peptide crude peptide into acetonitrile aqueous solution to obtain crude peptide solution; the method comprises the following specific steps:
dissolving the abamectin in acetonitrile water solution, and fully stirring until the abamectin is completely dissolved to obtain a crude abamectin solution;
insoluble particles in the crude abapatatin peptide aqueous solution are removed by a filter membrane, and the filtrate is collected.
Step two: taking the crude peptide solution, carrying out isocratic gradient elution by using a mixed solution of the solution A1 and the solution A2 and the solution B, and collecting eluted components to obtain a first purified substance; the method comprises the following specific steps:
taking an octaalkylsilane bonded silica chromatographic column as a stationary phase, 10% acetic acid as a mobile phase A1 and acetonitrile as a mobile phase B, carrying out isocratic elution at a detection wavelength of 260nm, then taking a 0.1% TFA aqueous solution as a mobile phase A2 and acetonitrile as a mobile phase B, carrying out gradient elution at a detection wavelength of 225nm, and collecting fractions containing the abamectin.
Step three: taking the first purified product, carrying out salt conversion gradient elution by using a mixed solution of the solution A3 and the solution B, and collecting an elution component to obtain a final purified product; the method comprises the following specific steps:
and (2) performing isocratic elution by taking a tetraalkylsilane bonded silica gel chromatographic column as a stationary phase, a pure water mobile phase A3 and acetonitrile as a mobile phase B, wherein the detection wavelength is 225nm, the volume fraction ratio of pure water to acetonitrile is 40% to 60%, and the isocratic elution time is 30-40 min, so as to complete the desalination treatment.
Step four: and (4) carrying out reduced pressure rotary steaming concentration and freeze drying on the final purified product to obtain the abapatatin finished product. The method comprises the following specific steps:
the water bath temperature of the rotary evaporator is 30 ℃, the vacuum degree is below-0.008 MP, and the freeze-drying is finished in a vacuum freeze-drying machine after the acetonitrile is removed.
Example 2, purification of crude abapa peptide experiment 1:
the abapa peptide was synthesized on a solid phase with a crude peptide purity of 69%.
Sample treatment: 3.0g of solid crude peptide was dissolved in acetonitrile water, and after stirring to completely dissolve the sample, the sample was filtered through a 0.45u filter, and the filtrate was collected for use.
First-step purification:
chromatographic conditions are as follows: the chromatographic column using the octaalkylsilane bonded silica gel as a stationary phase has the following diameters and lengths: 30mm by 250mm. 10% acetic acid is used as a mobile phase A1, acetonitrile is used as a mobile phase B, the detection wavelength is 260nm, isocratic elution is firstly carried out, then 0.1% TFA aqueous solution is used as a mobile phase A2, acetonitrile is used as a mobile phase B, the detection wavelength is 225nm, gradient elution is carried out, and the maximum sample loading amount of a single needle is 0.8g.
The specific elution gradient is shown in the table below:
collecting the abapatulin sample fraction with the purity of more than 99.0 percent and the single impurity of less than 0.15 percent.
And a second step of desalting:
the method is characterized in that a tetraalkylsilane bonded silica gel chromatographic column is used as a stationary phase column, and the diameter and the length are as follows: 50mm. Times.260 mm. Pure water is used as a mobile phase A3, acetonitrile is used as a mobile phase B, the detection wavelength is 225nm, isocratic elution is carried out, and the desalting treatment is completed. Wherein the volume fraction ratio of pure water to acetonitrile is 40 percent to 60 percent, the isocratic elution time is 30min, and the maximum sample loading amount of a single needle is 2.0g.
The specific elution gradients are shown in the following table:
all desalted samples were collected. Concentrating the collected target peak fraction by rotary evaporation at water temperature of 30 deg.C under reduced pressure (-below 0.008 MP), and freeze drying to obtain abapatatin with purity of 99.1% and purification yield of 66.7%.
Example 3: abapatide crude peptide purification experiment 2
The abapatulin was synthesized on a solid phase, and the purity of the crude peptide was 69%.
Sample treatment: 14.0g of the solid crude peptide was dissolved in acetonitrile water, and after stirring to completely dissolve the sample, the mixture was filtered through a 0.45u filter, and the filtrate was collected for use.
First-step purification:
chromatographic conditions are as follows: the chromatographic column using the octaalkylsilane bonded silica gel as a stationary phase has the following diameters and lengths: 50mm by 270mm. 10% acetic acid is used as a mobile phase A1, acetonitrile is used as a mobile phase B, the detection wavelength is 260nm, isocratic elution is firstly carried out, then 0.1% TFA aqueous solution is used as a mobile phase A2, acetonitrile is used as a mobile phase B, the detection wavelength is 225nm, gradient elution is carried out, and the maximum sample loading amount of a single needle is 2.2g.
The specific elution gradients are shown in the following table:
collecting the abapatulin sample fraction with the purity of more than 99.0 percent and the single impurity of less than 0.15 percent.
And a second step of desalting:
the method takes a tetraalkylsilane bonded silica gel chromatographic column as a stationary phase column, and has the following diameter and length: 50mm multiplied by 260mm, pure water is taken as a mobile phase A3, acetonitrile is taken as a mobile phase B, the detection wavelength is 225nm, isocratic elution is carried out, wherein the volume fraction ratio of the pure water to the acetonitrile is 40 percent to 60 percent, the isocratic elution time is 30min, and the maximum sample loading amount of a single needle is 4.0g.
The specific elution gradients are shown in the following table:
all desalted samples were collected. Concentrating the collected target peak fraction by rotary evaporation under reduced pressure (below 0.008 MP) at water temperature of 30 deg.C, and lyophilizing to obtain abapatatin with purity of 99.0% and purification yield of 70.3%.
Example 4 purification of abapatatin crude peptide experiment 3:
the abapa peptide was synthesized on a solid phase with a crude peptide purity of 71%.
Sample treatment: 15.0g of solid crude peptide was dissolved in acetonitrile water, and after stirring to completely dissolve the sample, the solution was filtered through a 0.45u filter, and the filtrate was collected for use.
First-step purification:
chromatographic conditions are as follows: the chromatographic column using the octaalkylsilane bonded silica gel as a stationary phase has the following diameters and lengths: 50mm by 270mm. Taking 10% acetic acid as a mobile phase A1, acetonitrile as a mobile phase B, detecting the wavelength of 260nm, performing isocratic elution, then taking a 0.1% TFA aqueous solution as a mobile phase A2, acetonitrile as a mobile phase B, detecting the wavelength of 225nm, performing gradient elution, and carrying out single-needle maximum sample loading of 2.2g.
The specific elution gradients are shown in the following table:
collecting the abapatulin sample fraction with the purity of more than 99.0 percent and the single impurity of less than 0.15 percent.
And a second step of desalting:
the method takes a tetraalkylsilane bonded silica gel chromatographic column as a stationary phase column, and has the following diameter and length: 50mm. Times.260 mm, pure water as mobile phase A3, acetonitrile as mobile phase B, detection wavelength of 225nm, isocratic elution, complete the desalination treatment. Wherein the volume fraction ratio of pure water to acetonitrile is 40% to 60%, the isocratic elution time is 30min, and the maximum sample loading amount of a single needle is 4.0g.
The specific elution gradients are shown in the following table:
all desalted samples were collected. Concentrating the collected target peak fraction by rotary evaporation at water temperature of 30 deg.C under reduced pressure (-below 0.008 MP), and freeze drying to obtain abapatatin with purity of 99.1% and purification yield of 73.0%.
Example 5: abapatide crude peptide purification experiment 4
The abapa peptide was synthesized on a solid phase with a crude peptide purity of 71%.
Sample treatment: 35.0g of solid crude peptide was dissolved in acetonitrile water, and after stirring to completely dissolve the sample, the solution was filtered through a 0.45u filter, and the filtrate was collected for use.
First-step purification:
chromatographic conditions are as follows: the chromatographic column using the octaalkylsilane bonded silica gel as a stationary phase has the following diameters and lengths: 100mm by 260mm. Taking 10% acetic acid as a mobile phase A1, acetonitrile as a mobile phase B, detecting the wavelength of 260nm, performing isocratic elution, then taking a 0.1% TFA aqueous solution as a mobile phase A2, acetonitrile as a mobile phase B, detecting the wavelength of 225nm, performing gradient elution, and carrying out single-needle maximum sample loading of 8.8g.
The specific elution gradients are shown in the following table:
collecting the abapatulin sample fraction with the purity of more than 99.0 percent and the single impurity of less than 0.15 percent.
And a second step of desalting:
the method is characterized in that a tetraalkylsilane bonded silica gel chromatographic column is used as a stationary phase column, and the diameter and the length are as follows: 50mm. Times.260 mm, pure water as mobile phase A3, acetonitrile as mobile phase B, detection wavelength of 225nm, isocratic elution, complete the desalination treatment. Wherein the volume fraction ratio of pure water to acetonitrile is 40% to 60%, the isocratic elution time is 30min, and the maximum sample loading amount of a single needle is 4.0g.
The specific elution gradients are shown in the following table:
all desalted samples were collected. Concentrating the collected target peak fraction by rotary evaporation at water temperature of 30 deg.C under reduced pressure (-below 0.008 MP), freeze drying to obtain abamectin with purity of 99.0% and purification yield of 73.8%
4 experiments show that the yield of the abamectin obtained by purifying the abamectin by the method is close to 70%, the purity of the obtained abamectin is more than 99.0%, and the method has high practical significance in production.
The above are only the main features and preferred embodiments of the present invention, and it should be noted that the above preferred embodiments should not be construed as limiting the present invention, and the scope of the present invention should be subject to the scope defined by the appended claims. It will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the spirit and scope of the invention, and should be considered to be within the scope of the invention.
Claims (1)
1. A purification method of abamectin is characterized by comprising the following steps: the method comprises the following steps: pretreating the abamectin crude peptide to dissolve the abamectin crude peptide into acetonitrile aqueous solution, removing insoluble particles by using a filter membrane, and collecting filtrate to obtain a crude peptide solution; step two: taking the crude peptide solution, carrying out isocratic and gradient elution on a mixed solution of the A1 solution, the A2 solution and the B solution, and collecting eluted components to obtain a first purified substance; the volume fraction ratio of the solution A1 to the solution B is 85% to 15%, and the isocratic elution time is 20min; the volume fraction ratio of the A2 solution to the B solution is 69%:31% → 45%:55%, and the gradient elution time is 50-60 min; taking an octaalkylsilane bonded silica chromatographic column as a stationary phase, 10% acetic acid as a mobile phase A1 and acetonitrile as a mobile phase B, carrying out isocratic elution at a detection wavelength of 260nm, then taking a 0.1% TFA aqueous solution as a mobile phase A2 and acetonitrile as a mobile phase B, carrying out gradient elution at a detection wavelength of 225nm, and collecting fractions containing abamectin; step three: taking the first purified product, carrying out salt conversion isocratic elution on a mixed solution of the solution A3 and the solution B, and collecting eluted components to obtain a final purified product; the volume fraction ratio of the pure water to the solution B is 40% to 60%, and the isocratic elution time is 30-40 min; performing isocratic elution by using a tetraalkylsilane bonded silica gel chromatographic column as a stationary phase, a pure water mobile phase A3 and acetonitrile as a mobile phase B, wherein the detection wavelength is 225nm, and thus completing desalting treatment; step four: carrying out reduced pressure rotary evaporation concentration and freeze drying on the final purified product, wherein the water bath temperature of a rotary evaporator is 30 ℃, and the vacuum degree is-0.008 MP; obtaining an abapatulin finished product; the solution A1 is a 10% acetic acid aqueous solution; the A2 solution is 0.1% TFA in water; the A3 solution is pure water; the solution B is 100% acetonitrile.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011638764.5A CN112724241B (en) | 2020-12-31 | 2020-12-31 | Purification method of abamectin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011638764.5A CN112724241B (en) | 2020-12-31 | 2020-12-31 | Purification method of abamectin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112724241A CN112724241A (en) | 2021-04-30 |
| CN112724241B true CN112724241B (en) | 2023-04-07 |
Family
ID=75608870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011638764.5A Active CN112724241B (en) | 2020-12-31 | 2020-12-31 | Purification method of abamectin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112724241B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114478749A (en) * | 2021-12-28 | 2022-05-13 | 深圳翰宇药业股份有限公司 | Purification method of abamectin |
| CN114349824A (en) * | 2021-12-31 | 2022-04-15 | 江苏诺泰澳赛诺生物制药股份有限公司 | Method for purifying linaclotide |
| CN117586377A (en) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | Long-acting abamectin compound |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109734794A (en) * | 2019-03-07 | 2019-05-10 | 苏州科技大学 | A kind of preparation method of A Bapa peptide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10996208B2 (en) * | 2017-04-28 | 2021-05-04 | Radius Health, Inc. | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
-
2020
- 2020-12-31 CN CN202011638764.5A patent/CN112724241B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109734794A (en) * | 2019-03-07 | 2019-05-10 | 苏州科技大学 | A kind of preparation method of A Bapa peptide |
Non-Patent Citations (1)
| Title |
|---|
| 戴好富等.流份收集和整理.《天然产物现代分离技术》.中国农业大学出版社,2006, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112724241A (en) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112724241B (en) | Purification method of abamectin | |
| CN103980351B (en) | The preparation method of pitressin, pitressin tannate | |
| CN112552376B (en) | Method for purifying vilacatide | |
| CN111057142B (en) | Purification method of teriparatide | |
| CN112661815B (en) | Method for purifying Tirzepatide | |
| CN107312073A (en) | A kind of method of purifies and separates Cetrorelix | |
| CN104672308A (en) | Method for preparing vasopressin tannate | |
| CN106167522A (en) | A kind of method of extensive isolated and purified teriparatide (Teriparatide) | |
| CN106317148B (en) | A method of extracting cordycepin from Cordyceps militaris | |
| CN103965291B (en) | Octreotide, the preparation method of octreotide acetate | |
| KR102322423B1 (en) | The Salt Exchange Method for Palmitoyl Tripeptide-1 | |
| CN113024658B (en) | Method for purifying liraglutide | |
| CN109467591B (en) | Purification method of cetrorelix | |
| CN114478750B (en) | Purification method of teriparatide | |
| CN115947829A (en) | Method for separating and purifying hirudin based on thrombin affinity magnetic microspheres and application thereof | |
| CN113683663A (en) | Purification method of organism-protected polypeptide crude product | |
| CN111848777A (en) | Method for purifying somaglutide | |
| CN115260293B (en) | Method for purifying ganirelix acetate | |
| CN113943362A (en) | Purification method of teduglutide dimer | |
| CN108047314A (en) | A kind of purification process of oxytocin | |
| CN103965296B (en) | Method for preparing angiotensin and angiotensin acetate | |
| RU2585105C1 (en) | Method of purifying triptorelin | |
| CA3076793C (en) | Integrated automated filtration for separation, washing and drying of peptide crystals | |
| CN114478749A (en) | Purification method of abamectin | |
| CN117603338A (en) | Purifying method of semagllutide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |